Re: David J. McConkey, Woonyoung Choi, Colin P. N. Dinney

Slides:



Advertisements
Similar presentations
MP60-03 PROSTATE CANCER IN THE ELDERLY
Advertisements

Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors1  Gottfrid.
The PSA Era is not Over for Prostate Cancer
Volume 64, Issue 3, Pages (September 2013)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Inflammatory Protein Serum Amyloid A1 Marks a Subset of Conventional Renal Cell Carcinomas with Fatal Outcome  Claudia Paret, Zorica Schön, Adrianna Szponar,
Volume 63, Issue 5, Pages (May 2013)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer  Karthik V. Giridhar, MD, Manish.
Volume 25, Issue 2, Pages (February 2014)
Nat. Rev. Urol. doi: /nrurol
Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 195, Issue 4, Pages e288-e289 (April 2016)
Volume 45, Issue 4, Pages (April 2004)
Volume 68, Issue 5, Pages (November 2015)
Re: Marcus G. Cumberbatch, Matteo Rota, James W. F
Volume 72, Issue 4, Pages (October 2017)
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Bladder Cancer: A Major Public Health Issue
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Elizabeth K. Bancroft, Rosalind A. Eeles
Volume 61, Issue 2, Pages (February 2012)
Volume 69, Issue 5, Pages (May 2016)
Prostate Cancer Detection: A View of the Future
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
On Molecular Classification of Bladder Cancer: Out of One, Many
On the Origin of Syn- and Metachronous Urothelial Carcinomas
Shaheen Alanee, Kasmintan Schrader, Kenneth Offit  European Urology 
Volume 64, Issue 3, Pages (September 2013)
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Prostate Cancer Epidemic in Sight?
Volume 59, Issue 1, Pages (January 2011)
The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Mark A. Rubin, Gabriele Girelli, Francesca Demichelis  European Urology 
Volume 72, Issue 4, Pages (October 2017)
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 62, Issue 4, Pages (October 2012)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 68, Issue 6, Pages e134-e135 (December 2015)
Volume 61, Issue 6, Pages (June 2012)
The Economic Costs of Overactive Bladder in Germany
Volume 62, Issue 3, Pages (September 2012)
Volume 50, Issue 5, Pages (November 2006)
Volume 55, Issue 6, Pages (June 2009)
Re: Christine McKillop
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Molecular Subtypes of Non-muscle Invasive Bladder Cancer
Testicular Cancer Variations in Time and Space in Europe
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
European Urology is “Your” Journal
Volume 25, Issue 2, Pages (February 2014)
Economic Burden of Bladder Cancer Across the European Union
Volume 26, Issue 8, Pages e4 (February 2019)
Volume 51, Issue 2, (February 2007)
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 53, Issue 2, Pages (February 2008)
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Bertrand Tombal, Richard Berges
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Molecular signatures are independent of tumor stage and grade.
Maximilian Burger, Ashish M. Kamat, David McConkey 
Presentation transcript:

Re: David J. McConkey, Woonyoung Choi, Colin P. N. Dinney Re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609–10  Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, Mattias Höglund  European Urology  Volume 67, Issue 4, Pages e73-e75 (April 2015) DOI: 10.1016/j.eururo.2014.08.063 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 The interrelationship between the Lund and MD Anderson (MDA) classification systems. (A) Clustered heat map visualization of the full Lund data set (n=308). Columns represent individual tumor samples and are grouped by taxonomy subtype. Rows correspond to the 500 most significant probes (seven-group analysis of variance [ANOVA]) that are differentially expressed across the full Lund data set. (B) Clustered heat map visualization of the full MDA data set (GSE48075), with tumor samples ordered by Lund subtypes and showing the same set of probes as in (A). (C) Visualization of the muscle-invasive urothelial bladder cancer subset of the Lund data (n=93) ordered by taxonomy subtype within each MDA subtype. Rows correspond to the top 500 most significant (three-group ANOVA) differentially expressed probes in the MDA discovery set (n=73). (D) The MDA discovery set visualized as in (C). (E) Diagrams showing the proportions of Lund and MDA subtype tumors in the respective data sets. In (A) and (B), as well as in (C) and (D), the figure widths are proportional to the number of tumors in the larger set. ANOVA=analysis of variance; MDA=MD Anderson Cancer Center; MI=muscle invasive; NMI=non–muscle invasive. European Urology 2015 67, e73-e75DOI: (10.1016/j.eururo.2014.08.063) Copyright © 2014 European Association of Urology Terms and Conditions